



Jason Hesham Melehani

- Fellow in Medicine
- Resident in Medicine

Bio

BIO

Dr. Melehani completed his medical and graduate research training at the University of North Carolina, Chapel Hill, earning both a medical degree and a doctorate in pharmacology. In his dissertation research, Dr. Melehani studied the molecular mechanism by which the innate immune system and *Staphylococcus aureus* interact. During his time in graduate and medical school, Dr. Melehani developed an interest in drug development - understanding the evidence supporting our use of medications in the clinic, as well as the process of discovering new targets and creating new medicines. To better understand this process, Dr. Melehani worked as a fellow at Hatteras Venture Partners, a healthcare- and biotechnology-focused venture capital firm in North Carolina. At Hatteras, Dr. Melehani worked closely with the investment team and managing partners to evaluate early-stage therapeutic development companies to find those with the greatest potential for transforming medicine.

Now, at Stanford, Dr. Melehani has completed residency training in Internal Medicine. He is a member of the Translational Investigator Program and is continuing training in Rheumatology and Pulmonary Medicine. He has an interest in immune-mediated pathogenesis in lung disease. His work currently focuses on studying how Sjogren's syndrome contributes to lung disease and lung transplant outcomes in patients with systemic sclerosis and other connective tissue diseases.

Publications

PUBLICATIONS

- **Inflammasome Activation Can Mediate Tissue-Specific Pathogenesis or Protection in *Staphylococcus aureus* Infection.** *Current topics in microbiology and immunology*
Melehani, J. H., Duncan, J. A.
2016; 397: 257-82
- ***Staphylococcus aureus* Leukocidin A/B (LukAB) Kills Human Monocytes via Host NLRP3 and ASC when Extracellular, but Not Intracellular.** *PLoS pathogens*
Melehani, J. H., James, D. B., DuMont, A. L., Torres, V. J., Duncan, J. A.
2015; 11 (6): e1004970
- **Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure.** *Frontiers in cardiovascular medicine*
Parry, T. L., Melehani, J. H., Ranek, M. J., Willis, M. S.
2015; 2: 25
- ***Toxoplasma* Co-opts Host Cells It Does Not Invade** *PLOS PATHOGENS*
Koshy, A. A., Dietrich, H. K., Christian, D. A., Melehani, J. H., Shastri, A. J., Hunter, C. A., Boothroyd, J. C.
2012; 8 (7)
- **CMF70 is a subunit of the dynein regulatory complex.** *Journal of cell science*
Kabutu, Z. P., Thayer, M., Melehani, J. H., Hill, K. L.

2010; 123 (Pt 20): 3587-95

- **The Trypanosoma brucei flagellum: moving parasites in new directions.** *Annual review of microbiology*
Ralston, K. S., Kabututu, Z. P., Melehani, J. H., Oberholzer, M., Hill, K. L.
2009; 63: 335-62